MediciNova Stock Forum

$MediciNova (MNOV.US)$ Looking for a update/data release from phase 2/3 of MN-166 in ALS patients!

$MediciNova (MNOV.US)$ Reuters· 5 mins ago
MediciNova Inc - Nih Awards $22 Million for Eap to Evaluate Mn-166 in ALS

$MediciNova (MNOV.US)$
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
MediciNova (NASDAQ:MNOV) has announced its support for an NIH-funded Expanded Access Protocol (EAP) trial to evaluate MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS). The NIH-NINDS has awarded $22 million for this intermediate-size trial, which will allow 200 ALS patients who are ineligible for the ongoing COMBAT-ALS trial to rec...

$MediciNova (MNOV.US)$
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
MediciNova, Inc. (NASDAQ:MNOV) has announced that an abstract regarding the COMBAT-ALS clinical trial of MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis (ALS) treatment has been accepted for poster presentation at the 35th International Symposium on ALS / MND. The symposium will take place from Dec...

$MediciNova (MNOV.US)$
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
MediciNova (NASDAQ:MNOV) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering ibudilast to alleviate various post-COVID symptoms, including anxiety, fatigue, depre...

$MediciNova (MNOV.US)$ Reuters· 2 mins ago
Medicinova Receives Notice of Allowance for New Patent Covering Mn-166 (Ibudilast) for the Prevention of Metastasis of Various Solid Cancer

$MediciNova (MNOV.US)$ Medicinova Announces Data From Phase 1B/2a Clinical Trial of Mn-166 (Ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (Asco) Annual Meeting 2024. Was safe and well tolerated.

$MediciNova (MNOV.US)$
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
MediciNova announced two poster presentations at the 92nd European Atherosclerosis Society (EAS) 2024 Congress. The presentations highlighted the efficacy, safety, and tolerability of MN-001 (Tipelukast) for non-alcoholic fatty liver disease (NAFLD) and its metaboli...

$MediciNova (MNOV.US)$ Reuters· 1 min ago
Medicinova - Gets Notice of Allowance for New Patent Covering Mn-166 (Ibudilast) for Treating Chlorine-Induced Acute Respiratory Distress Syndrome